title: [Allogenic stem cell transplantation following dose-reduced conditioning in patients with hematologic systemic diseases or solid tumors].
abstract: Allogeneic stem cell transplantation is an established treatment modality for a variety of hematologic malignancies. However this allogeneic stem cell transplantation carries the risk of severe complications which are partly due to the intensity of the conditioning regimen. Therefore, allogeneic stem cell transplantation has been so far only performed in younger patients with good performance status. Dose-reduced or non-myeloablative conditioning regimen has been proposed as an alternative that would allow exploiting the graft versus leukemia effect of allogeneic stem cell transplantation without severe toxicity. Clinical studies have shown that dose-reduced conditioning followed by allogeneic stem cell transplantation allows stable engraftment with lower toxicities which can be associated with long-term disease control. Therefore, dose-reduced conditioning followed by allogeneic stem cell transplantation can be offered to older and more debilitated patients who were no candidates for standard allogeneic stem cell transplantation.
authors.affiliation: Knochenmarktransplantation, Universitätsklinikum Hamburg-Eppendorf. nkroeger@uke.uni-hamburg.de
authors.forename: N
authors.initials: N
authors.lastname: Kröger
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy / Q000379:methods; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D006801:Humans; D010346:Patient Care Management / Q000379:methods*; D033581:Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods*; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous / Q000009:adverse effects / Q000379:methods; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents